Registry of CytoSorb Therapy in COVID-19 ICU Patients

Completed

Conditions studied: COVID-19

In brief

The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.

Key facts

Study ID

NCT04391920

Run by

CytoSorbents, Inc

People needed

138

Starts

2020-08-28

Expected to finish

2022-01-20

Last updated by the study team

2024-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed COVID-19
• Provision of CytoSorb therapy per Instructions for Use (IFU) of the CytoSorb device.

You may not qualify if…

• CytoSorb therapy for diseases other than COVID-19
• Survival unlikely within 24 hours (for prospectively enrolled patients)

Where it is running

• Medical Center of Aurora — Aurora, Colorado, United States
• University of Chicago Medicine — Chicago, Illinois, United States
• Franciscan Health Indianapolis — Indianapolis, Indiana, United States
• Baptist Memorial Hospital — Southaven, Mississippi, United States
• New York University Medical Center — New York, New York, United States
• West Virginia University — Morgantown, West Virginia, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.